Vol. 3 No. 3 (2023)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image

Published March 21, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (Keytruda), 200 mg IV every 3 weeks, or 400 mg IV every 6 weeks.
  • Indication: In combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 as determined by a validated test (CPS ≥ 10).